US Patent

US12533358 — Methods of treatment with elinzanetant

Method of Use · Assigned to Bayer Consumer Care AG · Expires 2045-05-14 · 19y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating vasomotor symptoms in a female subject by administering elinzanetant with a moderate CYP3A4 inhibitor.

USPTO Abstract

The present disclosure relates to methods of treating vasomotor symptoms in a female subject in need thereof by administering a therapeutically effective amount of elinzanetant or a pharmaceutically acceptable salt or deuterated thereof, wherein the female subject is concurrently administered with a moderate CYP3A4 inhibitor.

Drugs covered by this patent

elinzanetant (ELINZANETANT)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4402`	—	elinzanetant

Patent Metadata

Patent number: US12533358
Jurisdiction: US
Classification: Method of Use
Expires: 2045-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Consumer Care AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.